Brief: Ondine Biomedical Reports H1 2026 Operating Loss Increased To $15.90 Mln
30/09/2026 08:48
BRIEF-Ondine Biomedical Reports H1 2026 Operating Loss Increased To $15.90 Mln Sept 30 (Reuters) - Ondine Biomedical Inc OBI.L:
ONDINE BIOMEDICAL - 2026 INTERIM RESULTS & POST-PERIOD MOMENTUM
ONDINE BIOMEDICAL H1 EBIT USD -15.9 MILLION
ONDINE BIOMEDICAL - H1 2026 OPERATING LOSS INCREASED TO $15.90 MLN
ONDINE BIOMEDICAL - ANNOUNCES COMMENCEMENT OF EQUITY FUND RAISING PROCESS
Source text: ID:nRSd8605Wa
Further company coverage: OBI.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ondine Biomedical
See all newsAIM Ondine Biomedical - Capital Access Window - Ondine Biomedical Inc
Brief: Ondine Biomedical Confirms Total Gross Proceeds From Placing And Subscription Are £10 Million
Ondine Biomedical - Result of Fundraise, Restoration of Trading & TVR
Brief: Ondine Biomedical Announces A Proposed Fundraising Of About £10 Mln
Ondine Biomedical - Proposed c.£10m (C$18.88m) Fundraise